MP-GAL-3BP
Gal-3BP in serum/saliva of COVID-19 infected subjects
Gal-3BP is a multifunctional secreted protein of the innate immunity which is induced in cancer and viral infection.
Scientists at MediaPharma have identified Gal-3BP in serum or saliva as a predictive biomarker allowing doctors to screen COVID-19 infected subject who will develop severe complications and ICU.
MP-EV20-89Zr
EV20 labeled with zirconium-89 (89Zr)
Preclinical proof of activity established: in vivo localization of HER3+ human tumor xenografts.
In vivo localization of HER3-expressing cancer by immuno-PET.
MP-EV20/1959
Humanized bispecific antibody against HER3 and Gal-3BP
- Humanized bispecific antibody against HER3 and Gal-3BP.
- Preclinical proof of efficacy established: inhibition of HER3 activation/downstream signaling in various tumor cell lines and inhibition of capillary-like structures in HUVEC
- Indications in Oncology: cancers whose growth and progression depend on HER3 and Gal-3BP-promoted angiogenesis, including but not limited to those arising from breast, prostrate, ovary, lung, pancreas, stomach and melanoma.
MP-1959-ADC
Humanized Anti-Gal-3 BP Antibody-Drug Conjugate
MP-1959 is the humanized version of the murine monoclonal antibody SP-2 which recognizes human Gal-3 BP (also known as LGALS3BP, 90K or Mac-2 BP), a glycoprotein secreted in large amounts by the majority of tumor cells, which plays an important role in cell-cell and cell-extracellular matrix adhesion, angiogenesis and tumor invasion . MediaPharma’s scientists have generated a non-internalizing anti-Gal-3 BP Antibody-Drug Conjugate MP-1959.ADC. It consists of a humanized, engineered anti-Gal-3 BP monoclonal antibody (1959-sss) conjugated to highly potent maytansinoids (DM3 & DM4) via a disulfide bond to residual cysteine of the antibody’s light chain. Administration of LGS-ADC was effective in inducing a long lasting tumor shrinkage of tumor cell lines and patient-derived tumor xenografts.
Indications in Oncology: cancers overexpressing Gal-3 BP, including those arising from breast, prostrate, ovary, pancreas, lung, melanoma, glioblastoma and neuroblastoma.
MP-EV20-ADC
Humanized anti-HER3 Antibody-Drug Conjugate
